Abstract
IDEXX Laboratories will release third-quarter 2026 results on November 2, 2026 Pre-MKt; this preview summarizes the latest quarterly performance, consensus expectations for revenue and earnings, and key business drivers and analyst viewpoints shaping near-term stock performance.
Market Forecast
Street forecasts point to revenue of 1.19 billion US dollars for the quarter, up 11.02% year over year, with adjusted EPS around 3.74, up 19.36% year over year, and EBIT of 387.81 million US dollars, up 15.68% year over year; the company has not provided explicit current-quarter gross margin or net margin outlook. The core diagnostics and services engine is expected to lead growth through sustained utilization and continued enhancement of the test menu and digital tools, keeping recurring revenue momentum intact. The most prominent contributor is the Companion Animal Group, which generated 1.12 billion US dollars last quarter; company-level revenue grew 9.66% year over year, and this segment remains the primary growth driver.
Last Quarter Review
IDEXX Laboratories delivered second-quarter results featuring revenue of 1.22 billion US dollars (up 9.66% year over year), gross profit margin of 64.04%, GAAP net profit attributable to shareholders of 338.00 million US dollars, a net profit margin of 27.82%, and adjusted EPS of 4.27 (up 17.63% year over year). A notable highlight was operating leverage: EBIT reached 425.57 million US dollars (up 14.08% year over year), and GAAP net profit rose 21.54% quarter on quarter, reflecting strong execution and expense discipline. Main business composition remained concentrated in diagnostics and services: Companion Animal Group contributed 1.12 billion US dollars, Water delivered 58.56 million US dollars, Livestock, Poultry and Dairy contributed 35.18 million US dollars, and Other revenue was 4.60 million US dollars, while total company revenue advanced 9.66% year over year.
Current Quarter Outlook (with major analytical insights)
Core Diagnostics and Services
Diagnostics and services remain the central engine of quarterly performance, with Street models embedding a double-digit year-over-year revenue increase and high-teens growth in adjusted earnings per share. Given the mix of reference laboratory services, in-clinic instruments, and consumables, quarterly outcomes typically hinge on exam volumes, compliance and utilization trends, and the cadence of menu expansion. In the near term, the outlook benefits from continued adherence to diagnostics protocols in companion-animal care and the depth of the installed base, which supports recurring consumables demand even when instrument placements fluctuate. The second-quarter print confirmed robust profitability, with a 64.04% gross margin and 27.82% net margin, suggesting a strong starting point for the third quarter even as mix and expenses can vary sequentially. Pricing discipline and product mix remain levers for gross margin resilience; consumables and services typically carry higher margins than equipment sales, and recurring volume historically provides a stabilizing effect in volatile macro environments. Operationally, incremental margins are supported by scale in logistics, lab operations, and customer support, while targeted investments in R&D and software should sustain the pace of innovation without materially diluting profitability. The company’s portfolio continues to expand: new tests and workflow features can improve throughput and diagnostic yield per visit, which, in turn, boosts monetization per instrument and per account over time. The market will watch for management commentary on utilization trends through late September, including any geographic differences, to validate the revenue trajectory implied in consensus estimates.
Software and AI Integration
The recent acquisition of CoVetAI, a veterinary-focused AI clinical workflow software provider, reflects a continued push to deepen integration between diagnostics, data, and practice management. CoVetAI’s ambient scribe and workflow tools are designed to capture and organize consultation data, reducing administrative burden and enabling clinicians to spend more time on patient care—a dynamic that can indirectly support higher diagnostic adoption and consistency. While CoVetAI’s immediate financial contribution is not expected to be a major top-line driver for the just-ended quarter, its integration into the broader software ecosystem should enhance stickiness, raise the value proposition of cloud-based practice tools, and potentially increase diagnostics compliance. Over time, improved workflow and data capture can translate into better clinical decision-making and more frequent diagnostic testing within routine visits, reinforcing the recurring revenue profile. The company has also continued to broaden its in-clinic menu; for example, the Catalyst proBNP test, a dual-species cardiac marker, is positioned to help veterinarians assess heart disease in cats and dogs. This launch is scheduled to roll out in North America in October, with international expansion to follow, so the commercial impact should skew more to the fourth quarter and beyond rather than the quarter now being reported. Integrating AI-enabled software and a wider test menu supports a higher attachment rate for consumables and deeper engagement across clinics, which may enhance lifetime value per customer. As these digital and diagnostic capabilities converge, the combined platform can facilitate better clinical outcomes and operational efficiency, making the overall offering more compelling to both new and existing customers.
Stock-Price Drivers for This Quarter
For the third quarter, the most consequential swing factors are revenue delivery versus the 1.19 billion US dollars consensus, EPS performance relative to the 3.74 estimate, and management’s stance on the full-year outlook. In August, the company updated its full-year guide, raising its EPS outlook to a 14.69–14.94 range and narrowing revenue to 4.70–4.75 billion US dollars, which sets the bar for investor expectations heading into the seasonally important second half. Investors will look for reinforced confidence in that framework; commentary indicating that recurring diagnostics trends remain healthy would be viewed constructively given the implied double-digit revenue growth this quarter. Margins are the second driver: absent explicit current-quarter margin guidance, the prior-quarter 64.04% gross and 27.82% net margins form a benchmark—any signals of sustained cost discipline, favorable mix, or operating leverage should be supportive for EPS. New product flow and software integration form the third pillar; even if revenue impact is back-end loaded, evidence of strong clinician reception and early adoption for new tools can influence valuation multiples by strengthening visibility into future recurring growth. Lastly, management’s read on near-term ordering behavior for equipment, the cadence of placements, and any color on regional momentum will be parsed for implications into the holiday period and early 2027.
Companion Animal Group: Near-Term Performance Lens
Companion Animal Group is the principal revenue contributor and the clearest lens into third-quarter outcomes. Last quarter it generated 1.12 billion US dollars, a level consistent with the company’s trajectory toward mid- to high-single-digit organic growth in the period and double-digit progress in EPS. Within the group, reference laboratory and in-clinic diagnostics supply the recurring backbone; steady test utilization and compliance underpin both revenue quality and predictability. The market’s 11.02% year-over-year revenue growth forecast for the company suggests continued strength in underlying diagnostic demand even as equipment cycles can introduce quarterly noise. The segment’s revenue composition typically supports robust profitability, and second-quarter margin performance provides a favorable setup heading into the print. As the company broadens its diagnostic menu and brings AI-driven workflow into the customer experience, the likelihood of diagnostics being ordered consistently during visits should rise, supporting both per-visit revenue and customer retention. On the call, investors will focus on utilization mix, average revenue per instrument, and any commentary on recurring diagnostic testing rates to corroborate the implied growth path.
Water and Livestock, Poultry and Dairy: Steady Contributors
Beyond the core, Water revenue of 58.56 million US dollars and Livestock, Poultry and Dairy revenue of 35.18 million US dollars in the prior quarter illustrate the breadth of the portfolio. These businesses add diversification to the quarterly revenue profile and can modestly impact mix and margin depending on seasonal and regional dynamics. While their absolute dollar contribution is smaller than Companion Animal Group, their consistency can contribute to overall stability, particularly when core diagnostics and services growth is already healthy. For the quarter now being reported, investors will mainly treat these areas as steady contributors and look for qualitative signals on product uptake, geographic performance, and any operational efficiency initiatives. Taken together, the non-core lines should continue to augment the core franchise’s revenue base without detracting from profitability or capital allocation priorities.
Guidance Watch and Capital Allocation
Given the company’s updated full-year outlook in August, commentary around maintaining or refining that framework will be central to the market’s reaction. The raised EPS guidance to 14.69–14.94 and narrowed revenue outlook to 4.70–4.75 billion US dollars establish a visible path and imply continued execution in the back half. If management signals that third-quarter trends tracked in line with those parameters and that fourth-quarter catalysts—such as expanded test availability and ongoing software integration—are on course, investors may treat any quarter-to-quarter noise as transitory. From a capital allocation standpoint, the focus remains on reinforcing the diagnostics franchise, expanding software capabilities, and sustaining product innovation, with M&A oriented toward strategic adjacency rather than scale for its own sake. The recent software acquisition exemplifies this approach, potentially enhancing customer stickiness and future marginal economics without disrupting the operating model. The extent to which free cash flow conversion remains strong while funding growth initiatives will be another talking point that can influence sentiment on durability and valuation.
Analyst Opinions
Bullish opinions outweigh bearish views in the recent period, with multiple firms either maintaining or reiterating positive stances and no explicit sell ratings cited in the covered window. Barclays maintained an Overweight rating with a price target of 710 US dollars, citing a supportive setup for growth and profitability. JPMorgan adjusted its price target to 750 US dollars from 775 US dollars, remaining constructive on the earnings power reflected in Street models for the second half. Across recent updates, analysts noted that the average rating is overweight and the mean price target is 718.73 US dollars, consistent with expectations for continued double-digit year-over-year growth in revenue and high-teens growth in EPS this quarter. The positive view centers on three points: first, consensus forecasts for revenue of 1.19 billion US dollars and adjusted EPS of about 3.74 imply resilience in the core diagnostics and services engine; second, prior-quarter margins of 64.04% gross and 27.82% net provide a high-quality foundation for incremental operating leverage; and third, new product and software initiatives—such as the AI-driven workflow integration and the cardiac proBNP test introduction—bolster confidence in forward recurring revenue expansion. While some targets have been trimmed to reflect valuation discipline, the majority stance remains that execution on recurring diagnostics growth, steady utilization, and capital-light software enhancements should sustain the company’s growth algorithm into year-end. In sum, bullish commentary dominates, driven by the anticipated 11.02% year-over-year revenue increase for the quarter and a visible path to the full-year earnings framework articulated earlier in the year.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments